Sheba Medical Center

Ramat Gan, Tel Aviv 5262100

1 studies enrolling now · 4 studies all time

What they study most

Glioma, H3 K27M, HER2-Positive Primary Breast Cancer, Idiopathic Pulmonary Fibrosis, Residual Invasive Breast Cancer

Studies at this site

• ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study) — Recruiting now
• Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary Fibrosis — Stopped early
• A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05) — Running, not enrolling
• To Evaluate the Efficacy, Safety, and Tolerability of BBT-877 in Patients With IPF — Completed